Visualize the "fixed costs": The reality of the "bankruptcy risk" faced by the manufacturing industry that avoids adopting AI, claiming "it's still too early."

Eliminate "personalization risk" with AI. With an initial cost of only 200,000 yen for insurance, we will definitely change you and your company.

Current AI company president Takahashi: "8 years and 100 companies of business improvement achievements" systematized by AI! The resignation of "There's no way we can do it" will be broken by a professional's guaranteed success structure. No tedious PC input required, veteran insights semi-automatically transformed into knowledge. Eliminate individual dependency to zero, with an initial cost of 200,000 yen (less than a new employee's salary) plus a small monthly fee for immediate acquisition! It is an **“extremely inexpensive individual dependency elimination insurance”** that eliminates the hassle of budgets and approvals. Questions for AI: https://ytakahashivisionai.wixsite.com/my-site-4/q-a

• Other information systems

We developed a system that expands the functions of the electronic manifest ASP "KENET" to record the traceability from waste to the creation of recycled resources using blockchain technology. In May 2025, as a pre-service, we implemented registration functions from waste registration to the input of the recycling process and the completion of recycled resources. In January 2026, we newly developed functions for inventory management and shipping of recycled materials. The system also includes a CFP registration function for recycled resources, allowing for data input on the decarbonization effects of resource circulation. We aim to utilize the waste management functions cultivated over 18 years with KENET to advance into the field of resource circulation and work towards the effective use of waste for a circular society.

● This is a leak testing device for small electronic components that does not use fluorinated inert liquids (PFAS-free). ● There is no longer a need for unstable visual confirmation through liquid immersion testing. It adopts a quantitative testing method that allows for stable pressure leak testing. ● It is a tabletop leak testing device specifically for gross leaks, with accuracy equal to or greater than that of liquid immersion testing. ● The detectable range is approximately 1×10⁻² Pa·m³/s to 1×10⁻⁶ Pa·m³/s (varies depending on the target product). ● It is suitable for sealed structures ranging from a few millimeters to a maximum of 80 × 70 mm. Please feel free to contact us for more information!

The "Mechanical Stitching Method" by Nichinichisui Road Machinery Co., Ltd. is a new technique that allows for the repair of metal cracks without the application of heat. By using special bolts and reinforcement plates, cracks are physically removed, and repairs are made without causing any thermal impact to the base material. Repairs can be carried out in environments where open flames cannot be used. Since no heat is applied, the disassembly of equipment is minimized. ◎ For more details, please contact us. ◎ If you require a detailed technical explanation, please contact us.

The catalog subsidy is a grant system aimed at improving productivity and added value for small and medium-sized enterprises by selecting and implementing general-purpose labor-saving products such as IoT and robots from a pre-registered "product catalog." This initiative also aims to lead to wage increases. Features of the catalog subsidy: - Ability to choose general-purpose products from the catalog - Subsidy of up to 15 million yen - Support for applications from sales businesses - Ongoing public recruitment [Search for products that can be introduced with the catalog subsidy now] https://amada.shoryokuka-catalog.zeroplus-consul.co.jp/ *For more details, please refer to the related links or feel free to contact us.

Miami, Florida, January 10, 2026 - (JCN Newswire) - Promiscel, a clinical-stage cell immunotherapy company uniquely positioned in the development of potentially curative cell therapies for cancer patients, announced today that Dr. John Lee, our Chief Medical Officer, will present interim results of our lead asset, PRO CAR - 201A (a CAR T cell therapy targeting STEAP1). This therapy is currently being conducted as the first human Phase 1 clinical trial aimed at treating metastatic castration-resistant prostate cancer (mCRPC). The presentation will take place on January 12, 2025 (Monday) at 11:15 AM Pacific Standard Time at the Franciscan D (Ballroom Level) during the "Biotech Showcase 2026" in San Francisco, California.